Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
otlertuzumab + ibrutinib
- Development stage
- Unknown
- Lead developer
- Aptevo Therapeutics
- Modality
- scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Intravenous, Oral
01
Overview
Otlertuzumab + ibrutinib is an investigational combination therapy consisting of a CD37-directed ADAPTIR protein and a Bruton's tyrosine kinase (BTK) inhibitor. Otlertuzumab (TRU-016) is a humanized, single-chain, homodimeric therapeutic protein that targets CD37, a tetraspanin protein highly expressed on B-cell malignancies. It induces cell death through direct caspase-independent apoptosis and antibody-dependent cell-mediated cytotoxicity (ADCC). Ibrutinib is a small molecule that covalently binds to BTK, inhibiting the B-cell receptor signaling pathway which is essential for the survival and proliferation of malignant B cells. This combination was evaluated by Aptevo Therapeutics in a Phase 1b clinical trial for patients with chronic lymphocytic leukemia (CLL), aiming to leverage the complementary mechanisms of action of both agents to improve therapeutic outcomes in B-cell malignancies.
- Brand names
- Imbruvica
- Other names
- otlertuzumab + ibrutinib
02
Targets
BTK (Bruton tyrosine kinase)CD37
Beyond the preview
Go deeper on otlertuzumab + ibrutinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on otlertuzumab + ibrutinib.